María de Jesús Gallardo-Luna

María de Jesús Gallardo-Luna

Auto-generated profile, based on publicly available information

María de Jesús Gallardo-Luna

Department of Research and Technological Development, Directorate of Teaching and Research, Institute of Public Health from Guanajuato State, Guanajuato, Mexico

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2020 in Central Asian Journal of Global Health
Verified
Journal Article
Open access
PDF file
NPNicolás Padilla-Raygoza
Nicolás Padilla-Raygoza
ENEfraín Navarro-Olivos
Efraín Navarro-Olivos
MGMaría de Jesús Gallardo-Luna
María de Jesús Gallardo-Luna
FMFrancisco J Magos-Vázquez
Francisco J Magos-Vázquez
DDDaniel Alberto Díaz-Martínez
Daniel Alberto Díaz-Martínez
LDLuis Antonio Díaz-Becerril
Luis Antonio Díaz-Becerril
Introduction: In December 2019, cases of pneumonia of unknown cause arose in Wuhan, China. The causative agent was subsequently identified as 2019-nCoV and later called SARS-CoV-2. In Mexico, since January 2020 when the first cases were reported, the spread of the infection has occurred throughout the country. The state of Guanajuato, which is located in the center of the country, has taken isolation measures and closed public places in March 2020. The objective of this study was to analyze the evolution, symptoms, co-morbidities and deaths due to confirmed cases of COVID-19.Methods: An ecological study was designed from the database of confirmed cases of COVID-19 in the state of Guanajuato. Odds ratios and 95% confidence intervals were calculated for symptoms and co-morbidities in deaths of confirmed cases. Logistic regression models were generated adjusting for age group and gender.Results: Among the 838 confirmed cases in the state, cases with dyspnea and cyanosis showed more significant effect on death. Age group and gender had little involvement as confounders. For practically all comorbidities (including diabetes, hypertension, cardiovascular disease, chronic kidney disease, and immunosuppression), there was a significant effect (odds ratio greater than 2) on mortality from COVID-19. Age group showed a confounding effect on comorbidities and death, but not gender.Conclusion: The confirmed cases had more than twice the possibility of having comorbidities, compared with those who did not die.

30 March 2021 in Biomedical and Pharmacology Journal
Verified
Journal Article
Open access
NPNicolás Padilla-Raygoza
Nicolás Padilla-Raygoza
OVOscar Ulises Vega-Jimenez
Oscar Ulises Vega-Jimenez
AJAndrea García Juárez
Andrea García Juárez
MGMaría de Jesús Gallardo-Luna
María de Jesús Gallardo-Luna
ENEfraín Navarro-Olivos
Efraín Navarro-Olivos
DDDaniel Alberto Díaz-Martínez
Daniel Alberto Díaz-Martínez
With the emergence of a SARS-CoV-2 infection pandemic in China and its spread to other countries, mortality was shown to be high and to a greater extent if there were underlying pathologies. It is said {or an ecological analytical cross-sectional study, of the open records of confirmed and discarded cases for COVID-19 of the General Directorate of Epidemiology of the Secretary of Health of Mexico. A specific mortality of 9.79% is reported; being higher in men between the ages of 20 to 59 and over 60 years. Mortality rates from underlying diseases were higher than those reported in the USA in early May 2020. Asthma was found to be a protective factor for COVID-19 mortality. It is concluded that mortality was higher in the presence of comorbidities.

21 February 2024 in Acta Universitaria
Verified
Journal Article
Open access
PDF file
NRNicolás Padilla Raygoza
Nicolás Padilla Raygoza
GFGilberto Flores-Vargas
Gilberto Flores-Vargas
MGMaría de Jesús Gallardo-Luna
María de Jesús Gallardo-Luna
ENEfraín Navarro-Olivos
Efraín Navarro-Olivos
GMGuadalupe Irazú Morales-Reyes
Guadalupe Irazú Morales-Reyes
FMFrancisco Javier Magos-Vázquez
Francisco Javier Magos-Vázquez
The SARS-CoV-2 emergency and the covid-19 pandemic are a global public health phenomenon. The objective of this study was to analyze the time trends of covid-19 pandemic in Guanajuato and México. For the analysis, the public database of the National Epidemiological Surveillance System was used to show the indicators of covid-19 (monthly) corresponding to the Institute of Public Health of the State of Guanajuato and the rest of Mexico. Online graphs were designed with the counts; for comparisons, the rate ratio in semi-annual periods was chosen. Guanajuato showed a better performance at the beginning of the pandemic, but in January 2021 this trend seems to reverse. In later months the curves tend to be more similar between Guanajuato and the rest of Mexico. The explanations for this phenomenon may be the coordination of local actions, the biology of the pandemic itself, or vaccination plans. La emergencia de SARS-CoV-2 y la pandemia por covid-19 son un fenómeno de salud pública global. El objetivo de este trabajo fue analizar la evolución de la pandemia covid-19 en Guanajuato y en México. Para esto, se utilizó la base de datos pública del Sistema Nacional de Vigilancia Epidemiológica a fin de mostrar los indicadores de covid-19 (mensualmente) correspondientes al Instituto de Salud Pública del Estado de Guanajuato y el resto de México. Con los conteos se diseñaron gráficas en línea, y para comparaciones se optó por la razón de tasas en periodos semestrales. Guanajuato mostró un mejor desempeño al inicio de la pandemia, pero en enero de 2021, esta tendencia parece revertirse. En meses posteriores, las curvas tienden a ser más semejantes entre Guanajuato y el resto de México. Las explicaciones a este fenómeno pueden ser la coordinación de las respuestas locales, variaciones de la evolución de la pandemia o esquemas de vacunación.

30 June 2022 in Biomedical and Pharmacology Journal
Verified
Journal Article
Open access
E-Efraín Navarro -Olivos
Efraín Navarro -Olivos
F-Francisco J. Magos -Vázquez
Francisco J. Magos -Vázquez
MSMaría del Rosario Sánchez-Navarro
María del Rosario Sánchez-Navarro
DDDaniel A. Díaz-Martínez
Daniel A. Díaz-Martínez
MGMaría de Jesús Gallardo-Luna
María de Jesús Gallardo-Luna
NRNicolás Padilla- Raygoza
Nicolás Padilla- Raygoza
The Severe Acute Respiratory Syndrome Coronavirus 2, first detected in Wuhan, China, in 2019, had spread all over the world. It has caused the COVID-19 pandemic. Nowadays, there are effective and safe vaccines proven against this virus. The goal of this study was to verify it among health-care workers from the Institute of Public Health from Guanajuato State who received the BioNTech/Pfizer vaccine. For this purpose, we designed a quantitative cross-sectional study. The database was obtained from a previous strategy program by the Institute of Public Health from Guanajuato State called ENSERO-COVID. The available data consisted of two chemiluminescence measures of the IgG anti-Spike antibodies after one and six months of the BioNTech/Pfizer vaccine two doses application. The survey also included self-reported reactions to this vaccine. Frequency tables are presented for descriptive purposes. We performed the chi-square test, the z test for proportions, and the t-test for comparisons. Also, two linear regression models were fitted between the first and second chemiluminescence levels stratifying by prior infection by SARS-CoV-2. The database consisted of 177 records. Of them, 45 (25.4%) were positive for SARS-CoV-2 before vaccination. Only one person did not react to the two doses of vaccine application. Most of the self-reported reactions ceased in a short period -less than three days-. The differences observed, regarding chemiluminescence levels, between those with and without prior infection by SARS-CoV-2 were not statistically significant. More analyses are required to assess the long-term effects of the BioNTech/Pfizer ® vaccine.

6 September 2023
Verified
Book Chapter
Open access
PDF file
LPLuis Ulises Pérez-Arenas
Luis Ulises Pérez-Arenas
JPJessica Paola Plascencia-Roldán
Jessica Paola Plascencia-Roldán
GMGuadalupe Irazú Morales-Reyes
Guadalupe Irazú Morales-Reyes
GFGilberto Flores-Vargas
Gilberto Flores-Vargas
MGMaría de Jesús Gallardo-Luna
María de Jesús Gallardo-Luna
NPNicolás Padilla-Raygoza
Nicolás Padilla-Raygoza
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Due to the virus transmission and propagation since its origin, numerous mutations and variants have occurred. The concern relies on the ability to evade natural immunity and cause infections, even bypassing the immunity generated after the application of vaccines. The World Health Organization classified the variants into variants of interest (VOI) and variants of concern (VOC). From 2020 to 2021, the VOC variants were the alpha, beta, gamma, and delta types, currently adding the omicron variant. Onthe other hand, the VOI variants were the eta, iota, kappa, lambda, and mu types. The importance of their study leads to the problem of the possible generation of new waves of contagion, after their appearance, with a high possibility that the immunity known as herd achieved with some previous variant does not become effective.

8 March 2021 in International Journal of TROPICAL DISEASE & Health
Verified
Journal Article
Closed access
PDF file
NPNicolás Padilla-Raygoza
Nicolás Padilla-Raygoza
GFGilberto Flores-Vargas
Gilberto Flores-Vargas
CSCuauhtemoc Sandoval Salazar
Cuauhtemoc Sandoval Salazar
ENEfraín Navarro-Olivos
Efraín Navarro-Olivos
MGMaría de Jesús Gallardo-Luna
María de Jesús Gallardo-Luna
DDDaniel Alberto Díaz-Martínez
Daniel Alberto Díaz-Martínez
Aims: To compare the signs and symptoms in COVID-19 and another respiratory virus, among children. Study Design: A cross-sectional study was designed based on data from the National Epidemiological Surveillance System of the General Directorate of Epidemiology. Place and Duration of Study: All registries in database of confirmed and discarded cases of COVID-19 from Guanajuato State, Mexico in the period March-July 2020. Methodology: A confirmed case was one with clinical data mainly fever, cough and dyspnea, who had traveled to a country affected by the pandemic or had had contact with a confirmed case, and a positive rRT-PCR test for SARS -CoV-2. The cases discarded were those with the negative rRT-PCR test. The presence of clinical data among those under 18 years of age, of confirmed and discarded cases in the state of Guanajuato, was compared with Z for two proportions and P-value. Results: The sample included 446 confirmed cases and 2,134 discarded cases. The average age of those confirmed was 9.60 ± 5.46 years and 8.01 ± 5.39 years, among those discarded (P <.05). In both groups, male predominated (P = .91). Fever, myalgia, arthralgia, and conjunctivitis show statistically significant differences between confirmed and discarded cases (P < .05). Conclusion: There are not differences in signs and symptoms in COVID-19 and another respiratory virus. It is concluded that since the characteristics of COVID-19 are like the ones of other viral infections, the diagnosis cannot be made merely based on signs and symptoms.